Sight Diagnostics, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, has raised $71 million in Series D funding with participation from Koch Disruptive Technologies, Longliv Ventures and OurCrowd. This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity.
Read more here.
![[Surgical Theater in WFMZ]For the first time in Israel, Neurosurgery will be performed using the Surgical Theater® virtual and augmented reality technology at Rambam Medical Center](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
